Serum müllerian-inhibiting substance in Down's syndrome pregnancies

Human Reproduction

Volumn 22, Issue 4, 2007, Pages 1017-1020

  Seifer, David B ^a   MacLaughlin, David T ^b   Cuckle, Howard S ^c,d  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Leeds Screening Centre   (United Kingdom)

Author keywords

Antenatal screening; Down's syndrome; Marker; MIS; Ovarian reserve

Indexed keywords

MUELLERIAN INHIBITING FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; GLYCOPROTEIN; MULLERIAN INHIBITING HORMONE; MULLERIAN-INHIBITING HORMONE; TESTIS PEPTIDE HORMONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; INFERTILITY THERAPY; MATERNAL AGE; MATERNAL SERUM; PRENATAL SCREENING; STATISTICAL ANALYSIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; METHODOLOGY; MIDDLE AGED; OVARY; PREGNANCY; PRENATAL DIAGNOSIS; TIME;

ADULT; CASE-CONTROL STUDIES; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; GLYCOPROTEINS; HUMANS; MATERNAL AGE; MIDDLE AGED; OVARY; PREGNANCY; PRENATAL DIAGNOSIS; REPRODUCTIVE TECHNIQUES, ASSISTED; TESTICULAR HORMONES; TIME FACTORS;

EID: 34347214454     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del497     Document Type: Article

References (27)

1. Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, Themmen AP and Groome NP (2005) Development of a sensitive enzyme immunoassay for anti-Mullerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrin 63,267-273.
2. Bartmann AK, Araujo FM, Iannetta O, Paneto JC, Martelli L and Ramos ES (2005) Down's syndrome and precocious menopause. J Assist Reprod Genet 22(3),129-131.
3. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP et al. (1986) Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell 45(5),685-698.
4. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R and Taieb J (2003) Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18,323-327.
5. Ficicioglu C, Kutlu T, Baglam E and Bakacak Z (2006) Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 85(3),592-596.
6. Freeman SB, Yang Q, Allran K, Taft LF and Sherman SL (2000) Women with a reduced ovarian complement may have an increased risk for a child with Down's syndrome. Am J Hum Genet 66(5),1680-1683.
7. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM and Cohen-Bacrie P (2004) Serum anti-mullerian hormone/mullerian inhibiting substance appears to be a more discriminatory marker of ART outcome than follicular stimulating hormone, inhibin B or estradiol. Fertil Steril 82,1223-1229.
8. Hudson PL, Douglas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB and MacLaughlin DT (1990) An immunoassay to detect human Mullerian-Inhibiting Substance in males and females during normal development. J Clin Endocrinol Metab 70,16-22.
9. Kim JH, Seibel MM, MacLaughlin DT, Donahoe PK, Ransil BJ, Hametz PA and Richards CJ (1992) The inhibitory effects of mullerian-inhibiting substance on epitherial growth factor induced proliferation and progesterone production of human granulose-luteal cells. J Clin Endocrinol Metab 75(3),911-917.
10. Kline J, Kinney A, Levin B and Warburton D (2000) Trisomic pregnancy and earlier age at menopause. Am J Hum Genet 67(2),395-404.
11. Kline J, Kinney A, Reuss ML, Kelly A, Levin B, Ferin M and Warburton D (2004) Trisomic pregnancy and the oocyte pool. Hum Reprod 19(7),1633-1643.
12. La Marca A, Giulini S, Orvieto R, De Leo V and Volpe A (2005a) Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 20,1569-1572.
13. La Marca A, De Leo V, Giulini S, Orvieto R, Malmusi S, Giannella L and Volpe A (2005b) Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig 12,545-548.
14. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D and MacLaughlin DT (1996) Mullerian inhibiting substance in humans, normal levels from infancy to adulthood. J Clin Endocrinol Metab 81,571-576.
15. van Montfrans JM, Dorland M, Oosterhuis GJ, van Vugt JM, Rekers-Mombarg LT and Lambalk CB (1999) Increased concentrations of follicle-stimulating hormone in mothers of children with Down's syndrome. Lancet 353, 1853-1854.
16. Nasseri A, Mukherjee T, Grifo JA, Noyes N, Krey L and Copperman AB (1999) Elevated day 3 serum follicle stimulating hormone and/or estradiol may predict fetal aneuploidy. Fertil Steril 71(4),715-718.
17. Phillips OP, Cromwell S, Rivas M, Simpson JL and Elias S (1995) Trisomy 21 and maternal age of menopause. Does reproductive age rather than chronological age influence risk of nondisjunction? Hum Genet 95, 117-118.
18. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, Jong FH and Themmen AP (2002) Serum anti Mullerian hormone levels, a novel measure of ovarian reserve. Hum Reprod 17,3065-3071.
19. van Rooij IAJ, Tonkelaar I, Broekmans FJ, Looman CWN, Scheffer GJ, de Jon FH, Themmen APN and te Velde ER (2004) Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11(6 Pt 1),601-606.
20. van Rooij IAJ, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JDF, de Jong FH, Fauser BJCM, Themmen APN and te Velde ER (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility, a longitudinal study. Fertil Stertil 83,979-987.
21. Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, Haning RV and Flynn SD (1993) Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with follicular serum mullerian-inhibiting substance and androgen content. J Clin Endocrinol Metab 76(3),711-714.
22. Seifer DB, MacLaughlin DT, Christian BP, Feng B and Shelden RM (2002) Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77(3),468-471.
23. Takahashi M, Koide SS and Doanhoe PK (1986) Mullerian inhibiting substance as oocyte meiosis inhibitor. Mol Cell Endocrinol 47(3),225-234.
24. Tremellen KP, Kolo M, Gilmore A and Lekamge DN (2005) Anti-mullerian hormone as a marker of ovarian reserve. Aust NZ J Obstet Gynaecol 45,20-24.
25. de Vet A, Laven JSE, de Jong FH, Themmen APN and Fauser BCJM (2002) Anti-Mullerian hormone serum levels, a putative marker for ovarian aging. Fertil Steril 77,357-362.
26. Visser JA, de Jong FH, Laven JS and Themmen AP (2006) Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 131(1),1-9.
27. Warburton D (2005) Biological aging and the etiology of aneuploidy. Cytogenet Genome Res 111(3-4),266-272.